Phenominer Database Results (48 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 8 195.63 mg/mm 7.15 20.22 post excision weight measurement 0.0 0 if/tl 101779 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle end-diastolic diameter control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 8 8.09 mm 0.22 0.62 echocardiography 0.0 0 101787 2641
SS.ZUC-Leprfa+/+/Slc calculated heart left ventricle weight control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 8 948.71 mg 51.33 145.18 echocardiography 0.0 0 101795 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to total kidney weight ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 8 0.48 ml/min/g 0.02 0.06 serum creatinine analysis 0.0 0 101881 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 6 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101895 2642
SS.ZUC-Leprfa+/+/Slc heart left atrium weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left atrium mass male 126 days 6 2.06 mg/mm 0.23 0.56 post excision weight measurement 0.0 0 a/tl 101899 2642
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. liver mass male 126 days 6 312.19 mg/mm 25.29 61.95 post excision weight measurement 0.0 0 liv/tl 101903 2642
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. inguinal fat pad mass male 126 days 6 158.77 mg/mm 27.34 66.97 post excision weight measurement 0.0 0 if/tl 101907 2642
SS.ZUC-Leprfa+/+/Slc ratio of survivors of metabolic syndrome to total study population during a period of time control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total life span male 126 days 6 100.0 % necropsy 0.0 0 ratio of survivors of metabolic syndrome to total study population during a period of time (CMO:0003803) 101909 2642
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 8 0.32 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101755 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle posterior wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 8 1.56 mm 0.09 0.25 echocardiography 0.0 0 101791 2641
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 8 283.3 mg/mm 9.54 26.98 post excision weight measurement 0.0 0 liv/tl 101763 2641
SS.ZUC-Leprfa+/+/Slc pancreas weight to tibia length control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 8 42.2 mg/mm 3.86 10.92 post excision weight measurement 0.0 0 p/tl 101833 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle fractional shortening control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 8 32.62 % 1.67 4.72 echocardiography 0.0 0 101805 2641
SS.ZUC-Leprfa+/+/Slc blood high density lipoprotein cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 8 13.05 mg/dl 2.54 7.18 blood cholesterol analysis 0.0 0 101841 2641
SS.ZUC-Leprfa+/+/Slc systolic blood pressure control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. arterial blood pressure trait male 126 days 6 137.7 mmHg 3.04 7.45 tail cuff plethysmography 0.0 0 101889 2642
SS.ZUC-Leprfa+/+/Slc both kidneys wet weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. kidney mass male 126 days 6 0.78 g/cm 0.06 0.16 post excision weight measurement 0.0 0 101901 2642
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 8 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101759 2641
SS.ZUC-Leprfa+/+/Slc urine protein level control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total urine protein amount male 126 days 6 336.29 mg/d 19.58 47.96 urine protein analysis 0.0 0 101935 2642
SS.ZUC-Leprfa+/+/Slc epididymal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 8 1.22 g/cm 0.07 0.21 post excision weight measurement 0.0 0 ef/tl 101775 2641
SS.ZUC-Leprfa+/+/Slc E wave deceleration time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 8 33.89 ms 1.4 3.96 echocardiography 0.0 0 101817 2641
SS.ZUC-Leprfa+/+/Slc ejection fraction control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 8 69.1 % 2.22 6.28 echocardiography 0.0 0 101809 2641
SS.ZUC-Leprfa+/+/Slc blood alanine aminotransferase activity level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 8 20.5 U/l 0.5 1.41 automated blood analysis 0.0 0 101861 2641
SS.ZUC-Leprfa+/+/Slc urine total protein level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 8 7.51 mg/ml 0.17 0.49 urine protein analysis 0.0 0 101869 2641
SS.ZUC-Leprfa+/+/Slc body weight control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. body mass male 126 days 6 443.75 g 21.62 52.96 body weighing method 0.0 0 101885 2642
SS.ZUC-Leprfa+/+/Slc E/A wave ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 8 - 1.95 null 0.09 0.25 echocardiography 0.0 0 e/a 101813 2641
SS.ZUC-Leprfa+/+/Slc single kidney weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 8 30.3 g/cm 1.57 4.44 post excision weight measurement 0.0 0 k/tl 101767 2641
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 8 111.71 mg/mm 5.99 16.94 post excision weight measurement 0.0 0 rf/tl 101771 2641
SS.ZUC-Leprfa+/+/Slc heart ventricle septal wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 8 0.16 cm 0.01 0.01 echocardiography 0.0 0 101783 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle relative wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 8 39.0 % 2.0 5.66 echocardiography 0.0 0 101801 2641
SS.ZUC-Leprfa+/+/Slc heart isovolumetric relaxation time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 8 24.22 ms 2.42 6.84 echocardiography 0.0 0 101821 2641
SS.ZUC-Leprfa+/+/Slc time constant of left ventricular pressure decay control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 8 27.47 ms 0.82 2.32 echocardiography 0.0 0 101825 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 4 0.56 mmHg/mm 0.04 0.08 echocardiography 0.0 0 lvedp/lvdd 101829 2641
SS.ZUC-Leprfa+/+/Slc serum free fatty acids level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 8 15.07 mmol/l 0.66 1.86 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101853 2641
SS.ZUC-Leprfa+/+/Slc blood low density lipoprotein cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 8 25.0 mg/dl 6.0 16.97 blood cholesterol analysis 0.0 0 101845 2641
SS.ZUC-Leprfa+/+/Slc serum triglyceride level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 8 54.5 mg/dl 9.5 26.87 serum triglyceride analysis 0.0 0 101849 2641
SS.ZUC-Leprfa+/+/Slc serum creatinine level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 8 0.35 mg/dl 0.01 0.03 serum creatinine analysis 0.0 0 101873 2641
SS.ZUC-Leprfa+/+/Slc heart rate control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart pumping trait male 126 days 6 417.32 beats/min 13.71 33.58 tail cuff plethysmography 0.0 0 101891 2642
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. retroperitoneal fat pad mass male 126 days 6 178.02 mg/mm 31.55 77.28 post excision weight measurement 0.0 0 rf/tl 101905 2642
SS.ZUC-Leprfa+/+/Slc creatinine clearance to body weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. glomerular filtration trait male 126 days 6 0.91 ml/min/100g 0.06 0.15 urine creatinine analysis 0.0 0 101939 2642
SS.ZUC-Leprfa+/+/Slc creatinine clearance to total kidney weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. glomerular filtration trait male 126 days 6 1.25 ml/min/g 0.12 0.29 urine creatinine analysis 0.0 0 101937 2642
SS.ZUC-Leprfa+/+/Slc blood aspartate aminotransferase activity level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 8 48.5 U/l 0.5 1.41 automated blood analysis 0.0 0 101857 2641
SS.ZUC-Leprfa+/+/Slc serum urea nitrogen level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 8 24.25 mg/dl 0.69 1.95 serum urea nitrogen analysis 0.0 0 101865 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to body weight ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 8 0.43 ml/min/100g 0.03 0.08 serum creatinine analysis 0.0 0 101877 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to right ventricle weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 6 4.21 null 0.05 0.12 post excision weight measurement 0.0 0 lv/rv 101897 2642
SS.ZUC-Leprfa+/+/Slc tibia straight segment length control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. tibia length male 126 days 6 40.27 mm 0.24 0.59 body measuring method 0.0 0 101887 2642
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart mass male 126 days 6 0.33 g/cm 0.01 0.04 post excision weight measurement 0.0 0 101893 2642
SS.ZUC-Leprfa+/+/Slc blood total cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 8 68.0 mg/dl 2.0 5.66 blood cholesterol analysis 0.0 0 101837 2641